Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Reboxetine mesylate (FCE20124 mesylate) 是一种高效、选择性的,特异性的去甲肾上腺素再摄取抑制剂(NARI),能够抑制去甲肾上腺素再摄取(Ki=8 nM),可用于抑郁症的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 167 | 现货 | ||
5 mg | ¥ 368 | 现货 | ||
10 mg | ¥ 668 | 现货 | ||
25 mg | ¥ 1,320 | 现货 | ||
50 mg | ¥ 2,230 | 现货 | ||
100 mg | ¥ 3,330 | 现货 | ||
500 mg | ¥ 7,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 413 | 现货 |
产品描述 | Reboxetine mesylate (FCE20124 mesylate) is a norepinephrine reuptake inhibitor (Ki: 8.2 nM). |
靶点活性 | Norepinephrine reuptake:8.2 nM(Ki) |
体外活性 | Reboxetine dose-dependently and completely inhibits [3H]-dopamine uptake to the human norepinephrine transporters (hNET) with Ki value of 11 nM in Madin–Darby canine kidney (MDCK) cells. [1] |
体内活性 | Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively. [1] Reboxetine results in a significant reduction in the mean number of panic attacks and phobic symptoms in patients with DSM-III-R panic disorder. Reboxetine also results in improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores. [2] Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution. [3] Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex. [4] Reboxetine dose dependently decreases nicotine self-administration by ~60%. Repeated administration of Reboxetine (5.6 mg/kg) decreases nicotine self-administration and sucrose-maintained responding across the 14 sessions. [5] |
别名 | 瑞波西汀甲磺酸盐, FCE20124 mesylate, Edronax, PNU155950E mesylate, PNU 155950E, 甲磺酸瑞波西汀 |
分子量 | 409.5 |
分子式 | C19H23NO3·CH4O3S |
CAS No. | 98769-84-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 20.5 mg/mL (50 mM)
DMSO: 20.5 mg/mL (50 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 2.442 mL | 12.21 mL | 24.42 mL | 61.0501 mL |
5 mM | 0.4884 mL | 2.442 mL | 4.884 mL | 12.21 mL | |
10 mM | 0.2442 mL | 1.221 mL | 2.442 mL | 6.105 mL | |
20 mM | 0.1221 mL | 0.6105 mL | 1.221 mL | 3.0525 mL | |
50 mM | 0.0488 mL | 0.2442 mL | 0.4884 mL | 1.221 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Reboxetine mesylate 98769-84-7 GPCR/G Protein Neuroscience Adrenergic Receptor Norepinephrine disorder FCE20124 activity FCE-20124 Mesylate depression antidepressant 瑞波西汀甲磺酸盐 FCE20124 mesylate panic Beta Receptor FCE-20124 FCE 20124 Mesylate FCE 20124 inhibit Edronax PNU155950E Reboxetine PNU155950E mesylate PNU155950E Mesylate FCE20124 Mesylate Reboxetine Mesylate PNU 155950E Inhibitor 甲磺酸瑞波西汀 inhibitor